8:00 am Registration & Morning Coffee

8:55 am Chair’s Opening Remarks

Targeted Radiopharmaceuticals in the US: The Past, the Present & the Future

9:00 am Laying Out the Physical & Biological Principles: What Makes Targeted Radionuclide Therapy So Attractive

  • Munir Ghesani Chief of Nuclear Medicine, Icahn School of Medicine at Mount Sinai


  • Contrasting TRP against conventional external beam therapy, spotlighting toxicity, personalization, and systemic effects
  • Leveraging knowledge from oncology, bioengineering, radiochemistry, and physics to navigate developing next-generation TRP agents

9:30 am Re-186 Radiolabelled NanoLiposomes for Rare Brain & Spinal Cord Tumors

  • Norman La France Chief Medical Officer & Senior Vice President, PLUS Therapeutics


  • Exploring preclinical & clinical (Phase 1, Phase 2) data
  • Applying this to notoriously-difficult to treat recurrent glioblastoma
  • How effective is this for treating pediatric ependymoma & high-grade gliomas

10:00 am Speed Networking Break


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the TRP field and establish meaningful business relationships to pursue for the rest of the conference.

Discovery & Translational Track

Preclinical Evaluation of Emerging Radioisotopes: From Copper to Lead

11:00 am Pb-203 Image-Guided Pb-212 Alpha Particle Therapy for Cancer – Preclinical Evidence of a Potent Paradigm

  • Michael Shultz Co-founder & Chief Scientific Officer,, ViewPoint Therapeutics


  • Exploring the rationale behind exploring behind selecting newer isotopes
  • Considering side effects and efficacy: which combinations can complement these novel isotopes to address these challenges

11:30 am Copper-67 Theranostic: Its History, Availability & Promising Future


  • Previously limited in supply 64Cu/67Cu is a PET/beta emitting pair ideal for theranostic use
  • New production technology, exclusively licensed to Iotron, has enabled commercial production quantities of high SA material without reactor-associated risks
  • New studies underscore why 64Cu/67Cu diagnostic and treatment agents are gaining attention and use

11:45 am Unlocking the Potential of Theranostics

12:00 pm Small Molecule Alpha RPT Using At-211

  • David Mankoff Matthew J. Wilson Professor and Vice-Chair for Research,, University of Pennsylvania


  • Analyzing the approaches to small molecule RPT using At-211
  • Enhancing alpha therapy using a PARP-targeted platform

Clinical Track

Targets Beyond PSMA: Avoiding the Niche Label

11:00 am Development of TRP Agents Beyond PSMA & SSTR2


  • Reviewing clinical and business cases for TRP clinical indications
  • How TRP fits into the Ovarian cancer clinical pathway
  • Review of l TRP data in Ovarian cancer preclinical models

11:30 am Fibroblast Activation Protein (FAP)- A Target for Imaging & Therapy


  • Understanding the value of FAP as a target for radiopharmaceuticals
  • Highlighting current clinical development efforts with FAP targeted interventions
  • Reviewing SOFIE’s FAPI pipeline status

12:00 pm Choice Of Molecule & Isotope For Theranostic Indications; Exploring The Telix Pipeline

12:30 pm Lunch Break & Networking

Addressing TRP Toxicity: Chelators & Drug Design

1:30 pm Roundtable Discussion: Addressing the Key Limitation of Radiolabelled Antibodies with Pretargeting


  • Raising the slow clearance of radiolabelled antibodies due to their size
  • Designing structures that separate antibodies from radioactive agents to reduce excessive exposure to radiation
  • Achieving high affinity molecules that unite and join in vivo
  • Approaching this with differing dosing times – staggering administration to allow for the excess antibody to be cleared from the blood

2:00 pm Novel Approaches to Central Nervous System Targeted Radiotherapeutics

  • Marc Hedrick Chief Executive Officer, Plus Therapeutics Inc.


  • Analyzing drug formulation and dosing to reduce toxicity
  • Exploring local drug delivery as an administration route
  • An overview of the current pipeline and where it is headed

Targeted Radiopharmaceutical Applications: Case Studies of a Variety of Indications

1:30 pm Re-186 Radiolabeled NanoLiposomes for Leptomeningeal Metastases from Solid Tumors

  • Melissa Moore Vice President of Clinical Research, PLUS Therapeutics


  • Unpacking Preclinical and Clinical (Phase 1) Data
  • Applying this to Leptomeningeal Metastases
  • Planning the next steps

2:00 pm Session Reserved for Lantheus

2:30 pm Afternoon Break & Networking


Grab a coffee and explore our exhibition booths, network with your peers and more!

Improving the Accessibility of TRPs to Ensure That This is Treatment Available for All

3:30 pm Session Reserved for Invicro

4:00 pm How Should We Think About Commercial Aspects When Developing Radiopharmaceuticals?


  • What indications are particularly attractive?
  • How should we think about conventional competition?
  • What clinical settings could be conducive for earlier line use of RPs?

4:30 pm Chair’s Closing Remarks & End of Day One

5:00 pm Poster Networking Session


After the formal presentations have finished for the afternoon, the learning and networking carries on. The Poster Session is allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on the latest advancements in the TRP field.